GSK-209393

Study Sponsor: GSK

Study Title

A Phase I/IIa, dual-cohort, two-site, clinical trial evaluating the safety and activity of redirected autologous T cells expressing a high affinity TCR specific for NY-ESO-1 administered post ASCT in patients with advanced myeloma

Medicine or Vaccine (generic name)

GSK3377794

Sponsor Identification Number

209393

Trial Registry Identification Number(#'s)

NCT01352286

Medical Condition

Multiple Myeloma

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

http://www.gsk-clinicalstudyregister.com/study/209393

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT01352286

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

September 2019